 Connection
David Camidge to Chemoradiotherapy
This is a "connection" page, showing publications David Camidge has written about Chemoradiotherapy.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.354 |
|
|
|
-
Ladbury CJ, Rusthoven CG, Camidge DR, Kavanagh BD, Nath SK. Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy. Int J Radiat Oncol Biol Phys. 2019 10 01; 105(2):346-355.
Score: 0.156
-
Gadgeel S, Peters S, Mok T, Shaw AT, Kim DW, Ou SI, P?rol M, Wrona A, Novello S, Rosell R, Zeaiter A, Liu T, N?esch E, Balas B, Camidge DR. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol. 2018 11 01; 29(11):2214-2222.
Score: 0.150
-
Herbst RS, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, Sanchez-Hernandez A, Dakhil S, Camidge DR, Winzer L, Soo-Hoo Y, Cooper ZA, Kumar R, Bothos J, Aggarwal C, Martinez-Marti A. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022 10 10; 40(29):3383-3393.
Score: 0.048
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|